Compare iShares Core MSCI EAFE ETF (IEFA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Novartis AG — how do they compare? iShares Core MSCI EAFE ETF trades at $96.91, while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| IEFA | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $168.62 |
52-Week Low | $81.70 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% today amid a bearish technical signal. The ETF focuses on developed international equities excluding the U.S. and Canada, offering a 3.30% dividend yield with a low 0.07% expense ratio. Recent news highlights its role in diversification away from S&P 500 concentration risks. Key support and resistance levels are tightly clustered around $96-$97.
The outlook remains mixed; IEFA provides cost-effective exposure to stable international markets but faces headwinds from currency fluctuations and central bank policy shifts. Its bearish technical trend and neutral oscillators suggest near-term consolidation, while long-term investors may value its dividend income and geographic diversification benefits.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
